Press releases

1,536 human brain organoids modeling Alzheimer’s, Parkinson’s and frontotemporal dementia fly on SPX-35 to the International Space Station, as the company’s first Nanoligomer™ medicine prepares to enter human trials in ALS ERIE, Colo., Oct. 13, 2026 — Sachi Bio (Sachi Bioworks, Inc.), a clinical-stage biopharmaceutical company developing Nanoligomer™ medicines for neurodegenerative and inflammatory diseases, today sent 1,536 human brain organoids to the International Space St

Multi-Organ Tissue Models Head to the International Space Station to Accelerate Discovery for Neurological, Cardiac, Metabolic, and Systemic Diseases ERIE, CO – July 1, 2026 — Sachi Bio, a biotechnology company pioneering RNA-based therapeutics through its proprietary Nanoligomer™ platform, announced the successful completion of an orbital mission that advanced ADDISTM (Accelerated Drug Discovery in Space)—the company’s multi-organ, multi-indication discovery platform. The

In the realm of pharmaceuticals, the pursuit of innovation knows no bounds. Scientists and researchers constantly strive to leverage...